CoChat

Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases

Open access
Pham, Anh-Tuan, Ghilardi, Amanda Franceschini, Sun, Lijun · 2023 · Frontiers in Pharmacology

The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.

Abstract

Receptor-interacting serine/threonine kinase 2 (RIPK2) is a vital immunomodulator that plays critical roles in nucleotide-binding oligomerization domain 1 (NOD1), NOD2, and Toll-like receptors (TLRs) signaling. Stimulated NOD1 and NOD2 interact with RIPK2 and lead to the activation of nuclear factor kappa B (NF-κB) and mitogen-activated protein kinases (MAPK), followed by the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-12/23. Defects in NOD/RIPK2 signaling are associated with numerous inflammatory diseases, including asthma, sarcoidosis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), multiple sclerosis, and Blau syndrome. As RIPK2 is a crucial element of innate immunity, small molecules regulating RIPK2 functions are attractive to establish novel immunotherapies. The increased interest in developing RIPK2 inhibitors has led to the clinical investigations of novel drug candidates. In this review, we attempt to summarize recent advances in the development of RIPK2 inhibitors and degraders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2023.1127722

Cites

104 of 104 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 (A) Homodimeric packing of RIPK2 (PDB ID: 4C8B) (B) Details in the interface between two RIPK2 monomers. Monomers are shown in green and pink, respectively. The ligand is shown as golden (space-filled).
FIGURE 1 (A) Homodimeric packing of RIPK2 (PDB ID: 4C8B) (B) Details in the interface between two RIPK2 monomers. Monomers are shown in green and pink, respectively. The ligand is shown as golden (space-filled).CC BY · PubMed Central
FIGURE 2 NMR solution structure of human RIPK2 CARD (PDB ID: 2N7Z).
FIGURE 2 NMR solution structure of human RIPK2 CARD (PDB ID: 2N7Z).CC BY · PubMed Central
FIGURE 3 NODs/RIPK2 signaling pathways. After ligand binding, NODs oligomerize and form signaling complexes with RIPK2. RIPK2 is activated by auto-phosphorylation and further polyubiquitinated by E3 ligases. Ubiquitinated-RIPK2 turns on TAK1. pUb of both RIPK2 and IKKγ allows the TAK1-TABs complex to bind and phosphorylate IKKβ. IKK-mediated phosphorylation of the NF-κB inhibitor IκBα leads to its pUb and subsequent degradation through the UPS. Free NF-κB translocates to the nucleus and promotes the expression of downstream target genes for inflammatory cytokines and chemokines.
FIGURE 3 NODs/RIPK2 signaling pathways. After ligand binding, NODs oligomerize and form signaling complexes with RIPK2. RIPK2 is activated by auto-phosphorylation and further polyubiquitinated by E3 ligases. Ubiquitinated-RIPK2 turns on TAK1. pUb of both RIPK2 and IKKγ allows the TAK1-TABs complex to bind and phosphorylate IKKβ. IKK-mediated phosphorylation of the NF-κB inhibitor IκBα leads to its pUb and subsequent degradation through the UPS. Free NF-κB translocates to the nucleus and promotes the expression of downstream target genes for inflammatory cytokines and chemokines.CC BY · PubMed Central
FIGURE 4 Structure of RIPK2 type I kinase inhibitors.
FIGURE 4 Structure of RIPK2 type I kinase inhibitors.CC BY · PubMed Central
FIGURE 5 Co-crystal structure of 1 and RIPK2 (PDB ID: 5AR5). Ligand-receptor H-bonds are indicated by dashed lines. The DFG motif is shown in green.
FIGURE 5 Co-crystal structure of 1 and RIPK2 (PDB ID: 5AR5). Ligand-receptor H-bonds are indicated by dashed lines. The DFG motif is shown in green.CC BY · PubMed Central
FIGURE 6 Structure modification of 2 and GSK583. GSK2983559 was the first RIPK2 inhibitor which entered clinical studies.
FIGURE 6 Structure modification of 2 and GSK583. GSK2983559 was the first RIPK2 inhibitor which entered clinical studies.CC BY · PubMed Central
FIGURE 7 Co-crystal structure of RIPK2 in complex with 2 (PDB ID: 5J79) (A), GSK583 (PDB ID: 5J7B) (B), 3 (PDB ID: 6HMX) (C), 4 (PDB ID: 6RNA) (D), and GSK2983559 (PDB ID: 6RN8) (E).
FIGURE 7 Co-crystal structure of RIPK2 in complex with 2 (PDB ID: 5J79) (A), GSK583 (PDB ID: 5J7B) (B), 3 (PDB ID: 6HMX) (C), 4 (PDB ID: 6RNA) (D), and GSK2983559 (PDB ID: 6RN8) (E).CC BY · PubMed Central
FIGURE 8 Structure optimization of GSK’s pyrazole derivatives.
FIGURE 8 Structure optimization of GSK’s pyrazole derivatives.CC BY · PubMed Central
FIGURE 9 Co-crystal structure of RIPK2 in complex with NSC 11602 (PDB ID: 6SZE) (A) and 6 (PDB ID: 6UL8) (B).
FIGURE 9 Co-crystal structure of RIPK2 in complex with NSC 11602 (PDB ID: 6SZE) (A) and 6 (PDB ID: 6UL8) (B).CC BY · PubMed Central
FIGURE 10 Structure optimization of Norvatis’s RIPK2 inhibitors.
FIGURE 10 Structure optimization of Norvatis’s RIPK2 inhibitors.CC BY · PubMed Central
FIGURE 11 Co-crystal structure of 7 and RIPK2(PDB ID: 5W5J).
FIGURE 11 Co-crystal structure of 7 and RIPK2(PDB ID: 5W5J).CC BY · PubMed Central
FIGURE 12 Structure optimization of CHMFL-FLT3-165.
FIGURE 12 Structure optimization of CHMFL-FLT3-165.CC BY · PubMed Central
FIGURE 13 Structures of type II RIPK2 kinase inhibitors.
FIGURE 13 Structures of type II RIPK2 kinase inhibitors.CC BY · PubMed Central
FIGURE 14 Co-crystal structure of ponatinib and RIPK2 (PDB ID: 4C8B).
FIGURE 14 Co-crystal structure of ponatinib and RIPK2 (PDB ID: 4C8B).CC BY · PubMed Central
FIGURE 15 Structures of RIPK2 PROTACs. RIPK2 binders are highlighted in green. E3 ligase binders are highlighted in red.
FIGURE 15 Structures of RIPK2 PROTACs. RIPK2 binders are highlighted in green. E3 ligase binders are highlighted in red.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 104 references

Cited by

Metadata

Authors
Pham, A.-T., Ghilardi, A. F., & Sun, L.
Affiliations
Beth Israel Deaconess Medical Center (US)
Corresponding author
Sun, Lijun
Venue
Frontiers in Pharmacology
Published
2023-03-07
Volume
14
Pages
1127722-1127722
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4323364425
Cited by
40
References
103
Citations by year
2026: 9 · 2025: 13 · 2024: 11 · 2023: 7
FWCI
1.14
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
  • Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
Keywords
RIPK2, NOD2 signaling, Toll-like receptor signaling, NF-κB activation, MAPK signaling, inflammatory cytokines, inflammatory diseases, asthma, sarcoidosis, inflammatory bowel disease, multiple sclerosis, Blau syndrome, innate immunity, immunomodulation, small molecule drug candidates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.